Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Opinion
Video
This segment examines the evidence supporting cilta-cel in second-line therapy, highlighting key outcomes from the CARTITUDE trials and comparing them to other available second-line treatment options for multiple myeloma.
Video content above is prompted by the following:
- Please discuss the evidence supporting cilta-cel in second-line therapy.
- Which key outcomes from the CARTITUDE trials guide your decision to choose cilta-cel in the second-line setting?
- How do these findings compare with other available second-line treatments for multiple myeloma in this patient group?
Recent Videos
Related Content
